Peng An,Sitong Wan,Langrun Wang,Tiancheng Xu,Teng Xu,Yonghui Wang,Jin Liu,Keji Li,Xifan Wang,Jingjing He,Simin Liu
The inconsistent findings concerning the effects of vitamin D supplementation on cardiometabolic risk factors and the large heterogeneity in the published literature call for further research to identify sources of heterogeneity and potential effect modifiers. We performed a meta-analysis of randomized controlled trials (RCTs) published until March 2024 that reported estimates for the effects of vitamin D supplementation on cardiometabolic factors and relevant baseline covariates of RCT participants. A total of 17 656 participants from 99 RCTs were analyzed, and weighted mean differences (95% confidence intervals (CI)) for the intervention status were derived using random-effects modeling. Overall, compared with the placebo, vitamin D supplementation (median dose: 3320 IU·day−1; range 40–120 000 IU·day−1) had favorable effects on systolic blood pressure (SBP; −2.04 (−3.50, −0.59) mmHg; 1 mmHg = 0.133 kPa), diastolic blood pressure (DBP; −3.00 (−3.61, −2.39) mmHg), total cholesterol (TC; −0.12 (−0.21, −0.03) mmol·L−1), fasting blood glucose (FBG; −0.13 (−0.20, −0.05) mmol·L−1), hemoglobin A1C (A1C; −0.09 (−0.13, −0.05)%), and fasting blood insulin (FBI: −7.61 (−11.93, −3.30) pmol·L−1). The benefits of vitamin D were most evident in trials performed in non-Westerners, participants with baseline 25-hydroxyvitamin D (25[OH]D) lower than 15.0 ng·mL−1, non-obese (body mass index (BMI) < 30 kg·m−2), and older (age ≥ 50 years). The findings of this study underscore the need for personalized vitamin D intervention strategies that comprehensively account for individual patient characteristics (such as ethnocultural background, age, BMI, and circulating 25[OH]D level), intervention dosage, and intervention duration to optimize cardiometabolic health outcomes.
